Lunai Bioworks Inc. Common Stock
LNAI XNASAbout Lunai Bioworks Inc. Common Stock
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0 | $-1,799,404 | $-0.08 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get LNAI Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Lunai Bioworks Inc. Common Stock.